Statement by Ralph G. Neas, President and CEO, GPhA, Regarding H.B. 3734 in Massachusetts

Published Online: Tuesday, June 24, 2014

June 24, 2014-- “GPhA applauds the Massachusetts state legislature for passing legislation allowing interchangeable biologics to be automatically substituted at the pharmacy. Laws that avoid unnecessary requirements around these new medicines not only increase patient access, but also will enable public and private payors to achieve significant savings by facilitating substitution of interchangeable biologics for more expensive versions. Massachusetts provides a compelling example of policy that embraces a practical approach.

As we get closer to the point when patients across the U.S. will be able to access these safe alternatives to costly brand name biologics, GPhA continues to support legislation that does not add burdens to current pharmacy practice and upholds the intent of the Biologics Price Competition and Innovation Act (BPCIA).”
Latest Articles
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Latest Issues